T1	Participants 149 253	antiherpes drug valacyclovir on MRI-evident lesions in patients with relapsing-remitting MS in a phase 2
T2	Participants 443 558	Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment
T3	Participants 560 633	Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5
T4	Participants 1993 2118	In a subgroup of patients with high levels of disease activity who had more than one active MRI-evident lesion during 4 weeks
